Crossmark

Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective

Crossref DOI link: https://doi.org/10.1186/s12962-022-00399-4

Published Online: 2022-12-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Matsela, Lineo Marie

Cleary, Susan

Wilkinson, Thomas
License Information

Text and Data Mining valid from 2022-12-12

Version of Record valid from 2022-12-12
More Information

Article History

Received: 1 March 2022

Accepted: 9 November 2022

First Online: 12 December 2022

Declarations

:

: This study received ethical approval (HREC REF: 638/2020) from the human research ethics committee of the University of Cape Town.

: Not applicable.

: The authors declare that they.

Document is current

Any future updates will be listed below